Skip to main content

Main navigation

  • Rapid Reactions
  • Schizophrenia Foundations
  • Symptomatology
  • Patient Burden
  • Caregiver Perspectives
  • Psychopharmacology

Main navigation

  • Rapid Reactions
  • Schizophrenia Foundations
  • Symptomatology
  • Patient Burden
  • Caregiver Perspectives
  • Psychopharmacology

Psychopharmacology

Medication in hand
Can Peripherally Restricted Anticholinergics Like Trospium Reduce Risks?
Muscarinic Receptor
CME: I Love Muscarinic Control! Targeting the Muscarinic System in the Treatment of Schizophrenia
Medication
End of the Anticholinergic Era? Breaking Down the Anticholinergic System: Risks and Realities (Module 1)
Medication
CME: Psychopharmacolojourney: A Look at How Far We Have Come and Where We Might Go
Patient and provider
Schizophrenia Unfiltered, Part 3: Pathways to Novel Treatment 
Ins and Outs title slide
Ins and Outs of Antipsychotic Therapy for Schizophrenia
Prescribing
End of the Anticholinergic Era? Rationale and Evidence-Based Strategies for Deprescribing
Research
The Next Generation of Schizophrenia Treatment: Looking Beyond D2 and Exploring Novel Therapeutic Targets
Laboratory researcher
Overcoming Challenges in Schizophrenia Treatment
Neuron
New Mechanisms of Action in Psychiatry
Pharmacist
Developments in Treating Schizophrenia: New Mechanisms of Action and Methods of Delivery

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Page 3
  • Current page 4
  • Page 5
  • Next page Next ›
  • Last page Last »
© 2026 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use Cookie Policy